The stock of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has decreased by -1.95 when compared to last closing price of 56.84.Despite this, the company has seen a loss of -0.57% in its stock price over the last five trading days. Zacks Investment Research reported 2024-02-28 that Apellis’ (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
Is It Worth Investing in Apellis Pharmaceuticals Inc (NASDAQ: APLS) Right Now?
Company’s 36-month beta value is 0.90.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APLS is 98.84M, and currently, short sellers hold a 10.56% ratio of that floaft. The average trading volume of APLS on April 12, 2024 was 1.39M shares.
APLS’s Market Performance
The stock of Apellis Pharmaceuticals Inc (APLS) has seen a -0.57% decrease in the past week, with a -4.74% drop in the past month, and a -19.65% fall in the past quarter. The volatility ratio for the week is 4.34%, and the volatility levels for the past 30 days are at 4.14% for APLS. The simple moving average for the last 20 days is -1.64% for APLS’s stock, with a simple moving average of 3.73% for the last 200 days.
Analysts’ Opinion of APLS
Many brokerage firms have already submitted their reports for APLS stocks, with Jefferies repeating the rating for APLS by listing it as a “Buy.” The predicted price for APLS in the upcoming period, according to Jefferies is $80 based on the research report published on February 05, 2024 of the current year 2024.
Goldman gave a rating of “Buy” to APLS, setting the target price at $74 in the report published on November 09th of the previous year.
APLS Trading at -10.02% from the 50-Day Moving Average
After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.18% of loss for the given period.
Volatility was left at 4.14%, however, over the last 30 days, the volatility rate increased by 4.34%, as shares sank -2.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.52% lower at present.
During the last 5 trading sessions, APLS fell by -0.57%, which changed the moving average for the period of 200-days by -34.00% in comparison to the 20-day moving average, which settled at $56.58. In addition, Apellis Pharmaceuticals Inc saw -6.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLS starting from Deschatelets Pascal, who sale 69,107 shares at the price of $54.17 back on Apr 08 ’24. After this action, Deschatelets Pascal now owns 1,115,983 shares of Apellis Pharmaceuticals Inc, valued at $3,743,605 using the latest closing price.
Sullivan Timothy Eugene, the Chief Financial Officer of Apellis Pharmaceuticals Inc, sale 4,000 shares at $58.66 during a trade that took place back on Apr 01 ’24, which means that Sullivan Timothy Eugene is holding 93,338 shares at $234,640 based on the most recent closing price.
Stock Fundamentals for APLS
Current profitability levels for the company are sitting at:
- -1.37 for the present operating margin
- 0.85 for the gross margin
The net margin for Apellis Pharmaceuticals Inc stands at -1.37. The total capital return value is set at -0.98. Equity return is now at value -290.14, with -68.26 for asset returns.
Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -5.98. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -35.31.
Currently, EBITDA for the company is -515.42 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 16.81. The receivables turnover for the company is 1.87for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.10.
Conclusion
In a nutshell, Apellis Pharmaceuticals Inc (APLS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
